Jevtana Kit
Product Images NDC 0024-5824

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Jevtana (NDC 0024-5824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Jevtana 01)

Chemical structure of cabazitaxel, the active ingredient in Jevtana, shown with detailed molecular bonds and functional groups.*

FDA Label Image

Figure 1 (Jevtana 02)

A survival curve chart comparing the proportion of overall survival over time in months for two treatment groups: mitoxantrone plus prednisone, and cabazitaxel plus prednisone. The chart includes a legend with markers for each group, and a table below showing the number of patients at risk at various time points up to 30 months.*

FDA Label Image

Figure 2 (Jevtana 03)

A Kaplan-Meier survival curve chart displaying the probability of overall survival (%) over time in months. Two groups are compared: CBZ20+PRED and CBZ25+PRED, represented by blue diamond and green circle symbols respectively. The chart includes a number at risk table below the x-axis, showing patient counts at various time points for each group.*

FDA Label Image

Principal Display Panel (Kit Carton)

Kaplan-Meier curves displaying radiographic progression-free survival (rPFS) in months by treatment group in the intent-to-treat population. The graph compares cabazitaxel (solid blue line) versus enzalutamide or abiraterone (dashed red line) treatments, showing the number of subjects at risk over time in months along the x-axis and the Kaplan-Meier estimate on the y-axis.*

FDA Label Image

Principal Display Panel (60 mg/1.5 mL Vial Label)

Jevtana (cabazitaxel) Injection 60 mg/1.5 mL Before First Dilution kit by Sanofi-Aventis U.S. LLC. The packaging label shows this is a prescription drug, containing one single-dose Jevtana vial and one single-dose diluent vial for intravenous infusion only after second dilution. The carton includes warnings about cytotoxicity and dilution instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.